Literature DB >> 32676761

Proposed minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life.

Zahra Salehi1, Masoud Arabfard2, Omid Sadatpour1, Mina Ohadi3.   

Abstract

AIM: The aim of this study was to identify the minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life.
METHODS: We searched the Online Mendelian Inheritance in Man (OMIM) database to extract the validated human genes annotated (until March 2020) for five major disorders of pathophysiological overlap and sequential chronological occurrence in human, including multiple sclerosis, type 2 diabetes mellitus, Alzheimer's disease, vascular dementia, and Lewy body dementia. Gene co-expression and physical interaction networks were subsequently constructed for the overlapping genes across the selected disorders.
RESULTS: Remarkably, each of the gene co-expression and physical interaction networks consisted of single clusters (P = 0.0005 and P = 1 × 10-16, respectively). APP was the major hub in the integrated and tissue-specific co-expression networks, whereas insulin was the major hub in the physical interaction network. Several other hubs were identified across the identified networks, including TNF, VEGFA, GAPDH, and NOTCH1.
CONCLUSION: We propose the minimal co-expression and physical interaction networks and their single clustering in the development of cognition impairment in human mid and late life. This is a pilot study, warranting identification of more risk genes, using additional validated databases in the future.

Entities:  

Keywords:  Alzheimer’s disease; Cognition impairment; Lewy body dementia; Multiple sclerosis; Type 2 diabetes mellitus; Vascular dementia

Mesh:

Year:  2020        PMID: 32676761     DOI: 10.1007/s10072-020-04594-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  37 in total

1.  Prevalence of diabetes in patients with multiple sclerosis.

Authors:  Wiam I Hussein; Sethu S Reddy
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

2.  Author Correction: Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-22       Impact factor: 52.329

3.  Aging with multiple sclerosis: prevalence and profile of cognitive impairment.

Authors:  Mariana Branco; Luis Ruano; Emilio Portaccio; Benedetta Goretti; Claudia Niccolai; Francesco Patti; Clara Chisari; Paolo Gallo; Paola Grossi; Angelo Ghezzi; Marco Roscio; Flavia Mattioli; Fabio Bellomi; Marta Simone; Rosa Gemma Viterbo; Maria Pia Amato
Journal:  Neurol Sci       Date:  2019-04-23       Impact factor: 3.307

Review 4.  Comorbidity in multiple sclerosis: implications for patient care.

Authors:  Ruth Ann Marrie
Journal:  Nat Rev Neurol       Date:  2017-03-17       Impact factor: 42.937

5.  Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.

Authors:  Laura Negrotto; Mauricio F Farez; Jorge Correale
Journal:  JAMA Neurol       Date:  2016-05-01       Impact factor: 18.302

6.  A population-based cohort study suggests an increased risk of multiple sclerosis incidence in patients with type 2 diabetes mellitus.

Authors:  Wen-Hsuan Hou; Chung-Yi Li; Hsin-Hui Chang; Yu Sun; Chiang-Chin Tsai
Journal:  J Epidemiol       Date:  2017-01-27       Impact factor: 3.211

Review 7.  Impact of Metabolic Syndrome on Neuroinflammation and the Blood-Brain Barrier.

Authors:  Peter Van Dyken; Baptiste Lacoste
Journal:  Front Neurosci       Date:  2018-12-11       Impact factor: 4.677

Review 8.  Insulin and Autophagy in Neurodegeneration.

Authors:  Natália Prudente de Mello; Ana Maria Orellana; Caio Henrique Mazucanti; Geovanni de Morais Lima; Cristoforo Scavone; Elisa Mitiko Kawamoto
Journal:  Front Neurosci       Date:  2019-05-22       Impact factor: 4.677

9.  Risk factors for developing dementia in type 2 diabetes mellitus patients with mild cognitive impairment.

Authors:  Oana Albai; Mirela Frandes; Romulus Timar; Deiana Roman; Bogdan Timar
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-03       Impact factor: 2.570

10.  Prevalence, Influence Factors and Cognitive Characteristics of Mild Cognitive Impairment in Type 2 Diabetes Mellitus.

Authors:  Wei Li; Lin Sun; Guanjun Li; Shifu Xiao
Journal:  Front Aging Neurosci       Date:  2019-07-30       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.